Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
NEW YORK - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotech company with a market capitalization of approximately $21 billion, announced it will host a conference call and webcast on September 29, 2025, at 8:30 am ET to discuss recently released survival and safety data for pancreatic cancer patients treated with atebimetinib combined with mGnP. According to InvestingPro analysis, the company’s stock currently appears undervalued based on its Fair Value assessment.
The call will review data from 34 first-line pancreatic cancer patients with 9 months of median follow-up. These results were initially disclosed in a company statement on September 24 and will be featured in a poster presentation at the Pancreatic Cancer Action Network Scientific Summit on September 28.
Interested parties can access the live conference call through a webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for international locations, using conference ID 9502940. A replay will be available on the company’s website.
Atebimetinib is an oral, once-daily treatment classified as a Deep Cyclic Inhibitor of MEK, designed to target MAPK pathway-driven tumors common in pancreatic cancers. The drug is currently being evaluated in a Phase 2a trial for patients with advanced solid tumors including pancreatic cancer.
Immuneering, a clinical-stage oncology company, focuses on developing treatments for cancer patients. With an overall Financial Health Score rated as "GOOD" by InvestingPro, the company maintains a solid foundation for its research and development initiatives. The company’s announcement was made through a press release statement. Discover comprehensive analysis of over 1,400 healthcare stocks, including detailed Pro Research Reports that transform complex data into actionable insights, available exclusively on InvestingPro.
In other recent news, Immuneering Corporation announced the pricing of its public offering, aiming to raise approximately $175 million in gross proceeds. The offering includes 18,959,914 shares of Class A common stock priced at $9.23 per share. Additionally, Immuneering has given underwriters a 30-day option to purchase up to an additional 2,843,987 shares at the same price. Meanwhile, Teva Pharmaceutical Industries has been in the spotlight with several analyst updates. UBS raised its price target for Teva Pharma to $26.00, citing an improved outlook for the company’s branded business. Truist Securities and Goldman Sachs both maintained their Buy ratings on Teva, with Goldman Sachs highlighting positive Phase 3 trial data for Teva’s olanzapine long-acting injectable treatment. The trial results showed no cases of Post-Injection Delirium/Sedation Syndrome, a significant factor for the drug’s commercial prospects. These developments mark significant milestones for both Immuneering and Teva Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.